Berry Genomics
Berry Genomics is a biotechnology company that provides prenatal genetic testing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | CNY70.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| CNY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (5 %) | (8 %) | (4 %) | (16 %) | (6 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 34 % | 24 % | 5 % | (5 %) | 3 % | 8 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 24 % | 14 % | (8 %) | (19 %) | (37 %) | (18 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 7 % | 8 % | 9 % | 8 % | 10 % | 9 % |
Source: Company filings or news article
Related Content
Berry Genomics, founded in May 2010, is a leading company in clinical genomics and life sciences based in China. The company is dedicated to the research, development, and commercialization of genetic test technologies for clinical applications. Berry Genomics aims to assist in the accurate diagnosis of diseases throughout the entire human life cycle, thereby improving human health. The company pioneered the first Next-Generation Sequencing (NGS) based genetic test, Non-Invasive Prenatal Testing (NIPT), in China in 2010. Berry Genomics offers NGS-based tests for a variety of genetic diseases and cancers, from preconception to adulthood. The company is also at the forefront of clinical studies for the early detection of liver cancer. Berry Genomics serves healthcare providers and patients, operating primarily in the clinical genomics market. The business model revolves around the development and sale of advanced genetic testing solutions, generating revenue through the commercialization of these tests.
Keywords: clinical genomics, genetic testing, NGS, NIPT, disease diagnosis, life sciences, healthcare, liver cancer, R&D, China.